First-Line Treatment of Interstitial Cystitis (Painful Bladder Syndrome)
Clinical Scenario
Interstitial cystitis / painful bladder syndrome is characterised by suprapubic pelvic pain together with urinary urgency, increased urinary frequency, and nocturia. This protocol addresses initial management for patients presenting with this symptom complex.
Treatment Goals
The primary aim is meaningful reduction in suprapubic pelvic pain, urinary urgency, urinary frequency, and nocturia, with response assessed at 4 months.
Approach at a Glance
First-line management draws on a multimodal oral strategy — combining an FDA-approved agent specific to interstitial cystitis with complementary oral medications — alongside identification and avoidance of dietary triggers known to exacerbate symptoms. The full selection of agents, individualised combinations, and guidance on dietary modification is covered in the complete protocol.
References
- Pentosan polysulfate sodium is the only oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of interstitial cystitis.
- Multimodal therapy that includes pentosan polysulfate sodium (Elmiron), a tricyclic antidepressant, and an antihistamine is a relatively new approach to symptom relief based on advances in understanding of the complementary pathophysiologic mechanisms, but it remains to be evaluated in well-designed clinical effectiveness trials.
- Certain dietary products including, but not limited to, coffee, alcoholic beverages, citrus fruits, tomatoes, carbonated drinks, and spicy food have been associated with exacerbation of symptoms of interstitial cystitis/painful bladder syndrome.
- A small randomized controlled trial (RCT) of four months' duration supports the effectiveness of amitriptyline to reduce symptoms.
- Another small RCT demonstrated that oral cimetidine (Tagamet) significantly improved symptoms of suprapubic pain and nocturia.
View source ↗